Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Katherine E Lewis

Steven D Levin

Scott R Presnell

Stephen R Jaspers

Monica J Huber

Robert Mabry

Brian Wong

Kevin Hestir

David Bellovin

Emma Masteller

Julie Hambleton

Robert Sikorski

Alan J Korman

Mark J Selby

James William West

Nils Lonberg

Penny Thompson

Richard M Garcia

David J Fontana

George Robert Mabry, Iii

Andres A Gutierrez

Paul O Sheppard

Margaret Dow Moore

Ernestine A Lee

Robert R West

David W Taft

Janine Powers

Craig Ostrander

Penny E Phillips

Michael Carleton

Serena Kimi Perna

Ke Xu

Dimple Pandya

Joseph Grosso

Robert J Rosler

Anitra Wolf

Megan M Lantry

Brent Meengs

Christopher Mark Hill

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.

Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Treating inflammation with IL-17/IL-23 bispecific antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Use of an IL-17/IL-23 bispecific antibody for treating inflammation

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19

Antagonists of IL-17A, IL-17F, and IL-23P19

Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.

Dimeric fusion proteins and related compositions and methods

Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

IL-23 antagonists

Growing community of inventors

Seattle, WA, United States of America

Katherine E Lewis